CONRAY 30 Rx
Generic Name and Formulations:
Iothalamate meglumine 300mg/mL; soln for IV infusion; organically bound iodine 141mg/mL.
Indications for CONRAY 30:
For use in IV infusion urography, contrast enhancement of computed tomographic brain images and arterial digital subtraction angiography.
IV urography: Infuse at a rate of 50mL/min. 200–300mL (4mL/kg); max 300mL. Non-neoplastic conditions: 200–300mL. Arterial digital subtraction angiography: Carotid or vertebral arteries: 3–10mL; Aortic arch: 15–30mL; Subclavian and brachial arteries: 5–15mL; Major branches of the aorta: 5–30mL; Abdominal aorta: 10–30mL. Max total dose: 250mL.
Non-neoplastic conditions: <100lbs: 4mL/kg.
Myelography. Others: see full labeling.
Not for intrathecal use. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Avoid in homocystinuria. Subarachnoid hemorrhage. Multiple myeloma. Pheochromocytoma. Homozygous sickle cell disease. Primary or metastatic cerebral lesions; risk of convulsions. Advanced renal disease. Combined renal and hepatic disease. Severe hypertension. CHF. Recent renal transplant. Diabetes. Diabetic nephropathy. Hyperthyroidism. Endotoxemia. Elevated body temperatures. History of asthma/allergy. Elderly. Maintain adequate hydration. Pregnancy (Cat.B - Conray 30, 60; Cat.C - Conray 43). Nursing mothers: not recommended; avoid breastfeeding for 24hrs post-procedure.
Radiopaque contrast medium.
GI upset, facial flushing, body warmth; hypersensitivity reactions, cardiovascular reactions (eg, vasodilation, flushing, venospasm), inj site reactions, neurological reactions (eg, spasm, convulsions, aphasia, syncope, coma, death), endocrine reactions (eg, hypothyroidism), headache, shaking, chills, nephropathy.
Conray 30: Bottles (150mL)—12; Conray 43: Vials (50mL)—50; Bottles (250mL)—12; Conray 60: Vials (30mL, 50mL)—50; Bottles (100mL, 150mL)—12
Endocrinology Advisor Articles
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Nivolumab Associated With Thyroiditis in Patients With Cancer
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Diabetes May Decrease Ability to Feel Acid Regurgitation
- Gender-Related Association Between Physical Activity, Psychological Status in T2D
- Adverse Neurodevelopmental and Mental Health Outcomes in PCOS
- HbA1c Variability Predicts All-Cause Mortality in Type 2 Diabetes
- Choroidal Thickness Changes in Patients With Untreated Diabetes
- Pre-Pregnancy Fitness Lowers Gestational Diabetes Risk